Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

112 results about "Ficoll" patented technology

Ficoll is a neutral, highly branched, high-mass, hydrophilic polysaccharide which dissolves readily in aqueous solutions. Ficoll radii range from 2-7 nm. It is prepared by reaction of the polysaccharide with epichlorohydrin. Ficoll is a registered trademark owned by GE Healthcare companies.

Method for separating and extracting stem cells from placenta, umbilical cord or adipose tissue

The invention relates to a method for separating and extracting stem cells from a placenta, umbilical cord or adipose tissue, which comprises the following process steps: firstly mixing the placenta, umbilical cord or adipose tissue and a cell maintenance fluid according to the proportion by weight of 2.5-4:1, putting the mixture into a tissue crushing barrel, adding collagenase after crushing, uniformly mixing, hatching at the temperature of 37 DEG C, filtering, adding a precipitator, sucking a supernatant fluid after settling, centrifuging, removing the supernatant fluid, adding concentrated cells into a liquid of diatrizoate sodium-ficoll 400#, then centrifuging, collecting 10-15 ml of intermediate cell layer, washing with the cell maintenance fluid, counting the collected cells, and providing the cells for clinical use when the cell survival ratio is more than or equal to 95 percent. The invention not only realizes the separation and the extraction of all stem cells from the placenta, umbilical cord or adipose tissue, but also realizes industrialized production, and enables doctors to conveniently, safely and canonically obtain the adult stem cells in clinic and use the adult stem cells for treating the diseases of patients as using medicaments, thereby solving the bottleneck problem of difficult obtainment of adult stem cells in clinic and popularizing a cell treatment technology.
Owner:NINGXIA ZHONGLIANDA BIOPHYSICS

Method for carrying out in-vitro efficient amplification on natural killer (NK) cells, and application of method

The invention discloses a method for carrying out in-vitro efficient amplification on natural killer (NK) cells, and application of the method, aiming at solving the problems that the NK cells amplified by the traditional local method are small in amplification times, have cytokine dependency and cell aging, and the like. The method is characterized by comprising the following steps: 1, separating peripheral blood mononuclear cells (PBMCs) from human peripheral blood by using the traditional Ficoll-Paque density gradient centrifugation method; 2, carrying out 100 Grays irradiation treatment on artificial antigen presenting cells, and then storing by means of liquid nitrogen cryopreservation; 3, carrying out co-culture on the PBMCs and the artificial antigen presenting cells, subjected to the irradiation treatment, in a cell culture flask T75 of an RPMI 1640 medium, wherein the mass ratio of the PBMCs to the artificial antigen presenting cells is equal to 1: 2, and 50IU/mL of interleukin 2 is added into the RPMI 1640 medium; replacing the medium with a fresh medium every 2 to 3 days; 4, calculating the number of total cells in the cell culture flask T75 every 7 days, adding the same number of artificial antigen presenting cells subjected to the irradiation treatment into the cell culture flask T75 for stimulating again, and continuously culturing for 21 days to obtain the amplified NK cells. Therefore, after the method is adopted, a great deal of high-purity and high-quality NK cells can be obtained.
Owner:宁波枫林生物科技有限公司

Method for preparing anti-tumor combined immune cells DC (dendritic cell)-CIKs (cytokine induced killers) and NKs (natural killers) simultaneously and prepared combined immune cells

The invention discloses a method for preparing anti-tumor combined immune cells DC (dendritic cell)-CIKs (cytokine induced killers) and NKs (natural killers) simultaneously and the prepared combined immune cells. Ficoll density gradient centrifugation is used for efficient separation, a mononuclear cell is obtained, sufficient quantities of DCs, CIKs and NKs are obtained through cell culture bags and an immune cell induction culture system, and finally, the induced cells are cultured in a combined manner and applied to clinical treatment, so that a tumor killing effect is realized. The DCs, the CIKs and the NKs are subjected to induction culture respectively with adoption of TexMACS immune cell culture media produced by Miltenyi Biotec, autoserum, various cytokines and a combined culture technology, the cells are mixed for culture and application at certain point in time, application of fetal calf serum is avoided, the pollution rate of an exogenous pyrogen and an exogenous allergen is reduced, and the tumor killing activity of the finally mixed cells is enhanced simultaneously; with adoption of a cell culture bag technology, the cell contamination rate is reduced, and the method is suitable for clinical treatment and application.
Owner:TIANJIN PURUI SAIER BIOLOGICAL TECH CO LTD

Preparation method and application of human TSCMs (T memory stem cells)

The invention discloses a preparation method of human TSCMs (T memory stem cells), which comprises the following steps: (1) collecting peripheral venous blood with a blood cell separator or injector under aseptic conditions, and carrying out Ficoll-Hypaque density gradient centrifugation to obtain mononuclear cells; (2) putting the separated PBMCs (peripheral blood mononuclear cells) in a culture medium containing irritants and cell factors, regulating the cell density to (0.5-2)*10<6>/mL, transferring into a cell culture plate, culture bottle or culture bag, and culturing in an incubator; (3) after culturing the cells for 48-72 hours, replacing half of the culture solution, supplementing the equivalent culture solution to keep the cell density at (0.5-2)*10<6>/mL; and according to the cell growth state, harvesting the cells in the 10th-21st day. An anti-CD3 monoclonal antibody and an anti-CD28 monoclonal antibody are utilized as the irritants to activate the TSCMs, the cell factors rh IL-7, rh IL-15 and rh IL-2 are combined for irritation, and IM-12 is utilized to stop the stem cell differentiation, so that the cultured TSCMs have the common characteristics of both memory cells and stem cells, thereby providing a new optional scheme for clinical adoptive immunity cellular therapy.
Owner:SHENZHEN HORNETCORN BIOTECH

Method for separating and extracting stem cells from placenta, umbilical cord or adipose tissue

The invention relates to a method for separating and extracting stem cells from a placenta, umbilical cord or adipose tissue, which comprises the following process steps: firstly mixing the placenta, umbilical cord or adipose tissue and a cell maintenance fluid according to the proportion by weight of 2.5-4:1, putting the mixture into a tissue crushing barrel, adding collagenase after crushing, uniformly mixing, hatching at the temperature of 37 DEG C, filtering, adding a precipitator, sucking a supernatant fluid after settling, centrifuging, removing the supernatant fluid, adding concentrated cells into a liquid of diatrizoate sodium-ficoll 400#, then centrifuging, collecting 10-15 ml of intermediate cell layer, washing with the cell maintenance fluid, counting the collected cells, and providing the cells for clinical use when the cell survival ratio is more than or equal to 95 percent. The invention not only realizes the separation and the extraction of all stem cells from the placenta, umbilical cord or adipose tissue, but also realizes industrialized production, and enables doctors to conveniently, safely and canonically obtain the adult stem cells in clinic and use the adult stem cells for treating the diseases of patients as using medicaments, thereby solving the bottleneck problem of difficult obtainment of adult stem cells in clinic and popularizing a cell treatment technology.
Owner:NINGXIA ZHONGLIANDA BIOPHYSICS

Rapid amplification method of natural killer cells

The invention provides a rapid amplification method of natural killer cells. The rapid amplification method of the natural killer cells comprises the following steps: A, preparing a culture medium ofthe natural killer cells; B, carrying out isolation and culture of the natural killer cells; B1, removing anticoagulant peripheral blood into a centrifuge tube, performing centrifugation, absorbing upper-layer plasma into another centrifuge tube for later use; B2, diluting the plasma with physiological saline of which the volume is 0.5 to 2 times that of the plasma to obtain diluted blood; B3, separating PBMCs from the diluted blood with Ficoll-Paque; B4, resuspending 3 to 5*10<7>/ml PBMCs in a 40-60 ml culture vessel of a completely activated culture medium, and placing in an incubator of which the temperature is 35 to 40 DEG C and the CO2 concentration is 2 to 8% to be cultured for 2 to 4 days; B5, supplementing a cell expansion culture medium in the completely activated culture medium,and continuously carrying out culture to obtain the natural killer cells. The culture method of the invention can amplify a large number of the natural killer cells in a short time, and is lower in amount of the culture medium, and simple, convenient and safe in culture.
Owner:北京汇智驰康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products